Drug
Csl222
Csl222: highest development phase Phase 3, developed by CSL. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) NCT07080905 | Phase 3 | Hemophilia B |
| CSL222 (AAV5-hFIXco-Padua) NCT06003387 | Phase 3 | Hemophilia B |
Latest
No recent events.
Follow Csl222 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.